
Japanese Approval Is Sought for T-DXd in HER2+ Advanced Solid Tumors
A supplemental new drug application (sNDA) seeking the approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of adult patients with HER2-positive advanced or recurrent solid tumors that are refractory or intolerant to standard …